A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26- Year-Old Women

Trial Profile

A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26- Year-Old Women

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant nonavalent Merck (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck
  • Indications Cervical cancer; Human papillomavirus infections; Vulvovaginal cancer
  • Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms FUTURE 9
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 10 Oct 2017 Data from this trial were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) congress 2017, as reported in a Merck AG Media Release.
    • 10 Oct 2017 Results published in the Merck AG Media Release
    • 05 Sep 2017 Primary endpoint (Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Disease (End-of-study Update)) has been met, according to the results published in The Lancet
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top